Three patents currently held, every record listed here
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2041. from the record
Of the 5 now held by other companies, 5 name AbbVie Deutschland GmbH and Co. KG as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2041
Next term end
2
Patent families
When these terms end
Each bar runs from grant to computed term end. 2023 to 2043.
US 12,715,917
Methods of Using Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis
no later than May 13, 2040
US 12,721,847
Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors
Jan 8, 2041
US 11,813,257
Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors
Jan 8, 2042
20272031203520392043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
19 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jan 2042 · High confidence
Also notable
Ends May 2042 · High confidence
Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors
US 11,813,257
A family of 20 related applications built on the 2023 grant. Protection runs to 2042.
Matriptase 2 Inhibitors and Uses Thereof
US 12,428,415
Granted 2025. Too new for citation comparison; protection runs to 2042.
Formerly held, still cited
Notable
Ends no later than May 2040 · Medium confidence
A family of 7 related applications built on the 2026 grant. Too new for citation comparison; protection runs to 2040. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by AbbVie Deutschland GmbH & Co. KG
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 14, 2027The maintenance fee for Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors (US 11,813,257) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 3 of 3
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,721,847 | Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors In force · High confidence | In force | High confidence | |
| US 11,813,257 | Methods of Treating Erythropoietic Protoporphyria, X-Linked Protoporphyria, or Congenital Erythropoietic Porphyria with Glycine Transport Inhibitors In force · High confidence | In force | High confidence | |
| US 12,428,415 | Matriptase 2 Inhibitors and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 3: 5 patents in force now held by others · 19 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed